Yahoo Finance • 26 days ago
ST. PAUL, Minn., Oct. 7, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Christopher A. Klebanoff, MD, a physician-scientist at M... Full story
Yahoo Finance • last month
MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initia... Full story
Yahoo Finance • last month
ST. PAUL, Minn., Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T th... Full story
Yahoo Finance • 2 months ago
PHILADELPHIA, Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant... Full story
Yahoo Finance • 2 months ago
ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to Verismo Th... Full story
Yahoo Finance • 2 months ago
ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-... Full story
Yahoo Finance • 2 months ago
Soft earnings didn't appear to concern Bio-Techne Corporation's (NASDAQ:TECH) shareholders over the last week. Our analysis suggests that while the profits are soft, the foundations of the business are strong. Check out our latest analysi... Full story
Yahoo Finance • 2 months ago
Bio-Techne (NASDAQ:TECH) Full Year 2024 Results Key Financial Results Revenue: US$1.16b (up 2.0% from FY 2023). Net income: US$168.1m (down 41% from FY 2023). Profit margin: 14% (down from 25% in FY 2023). The decrease in margin was driv... Full story
Yahoo Finance • 3 months ago
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be paya... Full story
Yahoo Finance • 3 months ago
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased b... Full story
Yahoo Finance • 9 months ago
MINNEAPOLIS, Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at the WCBP conference held in... Full story
Yahoo Finance • 10 months ago
MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, An... Full story
Yahoo Finance • 11 months ago
MINNEAPOLIS, Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project.... Full story
Yahoo Finance • 11 months ago
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund outperformed the Russell 2000... Full story
Yahoo Finance • 11 months ago
Key Insights Bio-Techne's estimated fair value is US$57.87 based on 2 Stage Free Cash Flow to Equity With US$63.58 share price, Bio-Techne appears to be trading close to its estimated fair value The US$77.69 analyst price target for TECH... Full story
Yahoo Finance • last year
Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations MINNEAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today a... Full story
Yahoo Finance • last year
Bio-Techne Corporation (NASDAQ:TECH) shareholders might be concerned after seeing the share price drop 26% in the last quarter. But at least the stock is up over the last five years. However we are not very impressed because the share pric... Full story
Yahoo Finance • last year
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined 6.05% (Institutional Shares) in the quarter compared to a... Full story
Yahoo Finance • last year
MINNEAPOLIS, Sept. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) was pleased to host presentations by three industry experts yesterday at the CASSS CE Pharm conference in Philadelphia, PA. These industry experts highlighte... Full story
Yahoo Finance • last year
Bio-Techne Corp (NASDAQ:TECH) has recently been in the spotlight, drawing interest from investors and financial analysts due to its robust financial stance. With shares currently priced at 79.07, Bio-Techne Corp has witnessed a decline of... Full story